Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival

Full text
Author(s):
Show less -
Barbosa Pagnano, Katia Borgia [1] ; Bendit, Israel [2] ; Boquimpani, Carla [3] ; De Souza, Carmino Antonio [1] ; Miranda, Eliana C. M. [1] ; Zalcberg, Ilana [4] ; Larripa, Irene [5] ; Nardinelli, Luciana [2] ; Silveira, Rosana Antunes [1] ; Fogliatto, Laura [6] ; Spector, Nelson [7] ; Funke, Vaneuza [8] ; Pasquini, Ricardo [8] ; Hungria, Vania [9] ; Chiattone, Carlos Sergio [9] ; Clementino, Nelma [10] ; Conchon, Monika [11] ; Beatriz Moiraghi, Elena [12] ; Lopez, Jose Luis [13] ; Pavlovsky, Carolina [14] ; Pavlovsky, Miguel A. [14] ; Cervera, Eduardo E. [15] ; Antonio Meillon, Luis [16] ; Simoes, Belinda [17] ; Hamerschlak, Nelson [18] ; Magarinos Bozzano, Alicia Helena [19] ; Mayta, Ernesto [20] ; Cortes, Jorge [21] ; Bengio, Raquel M. [5] ; LALNET, Latin Amer Leukemia Net
Total Authors: 30
Affiliation:
Show less -
[1] Univ Estadual Campinas, UNICAMP, Hemoctr, BR-13083878 Campinas, SP - Brazil
[2] Univ Sao Paulo, Lab Biol Tumoral, Sao Paulo, SP - Brazil
[3] Hemorio, Rio De Janeiro, RJ - Brazil
[4] Inst Nacl Canc, Rio De Janeiro, RJ - Brazil
[5] Acad Nacl Med Buenos Aires, Inst Invest Hematol, Buenos Aires, DF - Argentina
[6] Hosp Clin Porto Alegre, Porto Alegre, RS - Brazil
[7] Univ Fed Rio de Janeiro, Rio De Janeiro, RJ - Brazil
[8] Univ Fed Parana, BR-80060000 Curitiba, Parana - Brazil
[9] Santa Casa Sao Paulo, Sao Paulo, SP - Brazil
[10] Univ Fed Minas Gerais, Belo Horizonte, MG - Brazil
[11] Hosp Santa Marcelina, Sao Paulo, SP - Brazil
[12] Hosp Ramos Mejia, Buenos Aires, DF - Argentina
[13] Banco Municipal Sangre DC, Caracas - Venezuela
[14] FUNDALEU, Buenos Aires, DF - Argentina
[15] INCAN, Mexico City, DF - Mexico
[16] Ctr Med Nacl Siglo XXI, Mexico City, DF - Mexico
[17] Univ Sao Paulo, BR-14049 Ribeirao Preto, SP - Brazil
[18] Hosp Israelita Albert Einstein, Sao Paulo, SP - Brazil
[19] Hosp Maciel, Montevideo - Uruguay
[20] Inst Oncol Nacl, Panama City - Panama
[21] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 - USA
Total Affiliations: 21
Document type: Journal article
Source: CANCER INVESTIGATION; v. 33, n. 9, p. 451-458, 2015.
Web of Science Citations: 8
Abstract

This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n=31, 16%). Progression-free (PFS) and overall survival (OS) at 5 years were lower in patients with BCR-ABL mutations (43% vs. 65%, p=0.07 and 47% vs. 72%, p=0.03, respectively) and in those with the T315I mutation (p=0.003 and p=0.03). OS and PFS were superior in subgroup who switched to second generation inhibitors (SGIs) after IM failure (OS: 50% vs. 39% p=0.01; PFS: 48% vs. 30% p=0.02). BCR-ABL mutations conferred a significant poor prognosis in CML patients. (AU)